173943-90-3

Basic information

• Product Name: (+/-)-1'-<3-(3,4-dichlorophenyl)-4-methylaminobutyl>spiro
• Synonyms: (+/-)-1'-<3-(3,4-dichlorophenyl)-4-methylaminobutyl>spiro
• CAS NO: 173943-90-3
• Molecular Weight: 419.394
• Mol File: 173943-90-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (+/-)-1'-<3-(3,4-dichlorophenyl)-4-methylaminobutyl>spiro(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-1'-<3-(3,4-dichlorophenyl)-4-methylaminobutyl>spiro(173943-90-3)
• EPA Substance Registry System: (+/-)-1'-<3-(3,4-dichlorophenyl)-4-methylaminobutyl>spiro(173943-90-3)

Safety Data

• Hazardous Substances Data: 173943-90-3(Hazardous Substances Data)

Upstream product

• 152298-51-6 2-(2-Hydroxyethyl)-2-(3,4-dichlorobenzene)ethanamine 
• 142001-76-1 tert-Butyl N-methyl-N-[2-(3,4-dichlorophenyl)-4-methanesulphonyloxybutyl]carbamate 
• 142001-75-0 tert-Butyl N-methyl-N-[2-(3,4-dichlorophenyl)-4-hydroxybutyl]carbamate 
• 152298-54-9 N-[2-(S)-(3,4-dichlorophenyl)-4-hydroxybutyl]-N-methylamine 
• 173943-89-0 tert-butyl (+/-)-N-[2-(3,4-dichlorophenyl)-4-(spiro[isobenzofuran-1(3H),4'-piperidine]-1'-yl)butyl]-N-methylcarbamate 

Relevant articles and documents

Spiro-substituted piperidines as neurokinin receptor antagonists. II. Syntheses and NK2 receptor-antagonistic activities of N-[2-aryl-4-(spiro- substituted piperidin-1'-yl)butyl]carboxamides

In the course of our research on spiro-compounds as neurokinin receptor antagonists, N-[2-aryl-4-spiro-substituted piperidin-1'-yl)butyl]carboxamides were designed, based on YM-35375 (3) as a lead compound, and evaluated for NK2 receptor-antagonistic activities. Some derivatives inhibited the binding of radio-labeled neurokinin A to the NK2 receptor with IC50 values at the level of 10-9. Among these compounds, (±)-1'-[4-(N-benzoyl-N-methylamino)- 3-(3,4-dichlorophenyl)butyl]spiro[benzo[c]thiophene-1(3H), 4'-piperidine] 2- oxide (58, YM-38336) showed 10 times more potent NK2 receptor binding affinity than compound 3 (IC50 values of 8.9 and 84nM, respectively). It showed more potent inhibitory activity (ID50 20μg/kg (i.v.)) against [β- Ala8]-NKA(4 - 10)-induced bronchoconstriction in guinea pigs than compound 3 (ID50 41 μg/kg (i.v.)). This compound was also effective intraduodenally in the same model, exhibiting an ID50 value of 0.41 μg/kg.